Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595814 · ClinicalTrials.gov registry record
Global Non-interventional Heart Failure Disease Registry
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- 18,805
- Enrollment target
NCT02595814: Clinical Trial study, sponsored by Novartis Pharmaceuticals.
NCT02595814 is a clinical trial that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 18,805 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02595814 was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- 18,805 participants
- Enrollment target
Study Summary
The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,805 participants |
| Start Date | 2014-07-23 |
| Est. Completion | 2018-03-31 |
Why NCT02595814 stopped before completion
NCT02595814 is an observational study that tracks outcomes without assigning an intervention. Its 18,805 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02595814 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02595814 about?
NCT02595814 is a clinical study titled "Global Non-interventional Heart Failure Disease Registry". The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designe...
What is the current status of trial NCT02595814?
This trial is currently terminated. The enrollment target is 18,805 participants. The study started on 2014-07-23. Estimated completion is 2018-03-31.
Who is sponsoring clinical trial NCT02595814?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04372875 · 18,500 participants · NA
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
- NCT05555095 · 19,331 participants
Examining Digital Health Care Delivery Models Through Medicaid Collaborative
- NCT07152249 · 19,480 participants · NA
Advancing Strategies to Optimize the PerIopeRativE Management of PostOperative Nausea and Vomiting (ASPIRE-PONV) Trial
- NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI